AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 62 min read$ABBV

AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma

AbbVie (ABBV) and Genmab (GMAB) reported positive Phase 3 trial results for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma. The combination reduced disease progression risk by 51% in patients with IPI scores of 2-5. The drug is already approved in certain lymphoma indications. Both companies plan to discuss next steps with regulators. ABBV and GMAB shares showed mixed movements.

Original reporting
rttnews.com
Published Oct 6, 2026, 5:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 6:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma — source image
Source · rttnews.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

The data could accelerate regulatory discussions and increase market expectations for a new lymphoma therapy.

02

Market read

First‑report trial success is a material catalyst for both stocks and the broader oncology sector.

03

What to watch

Potential competition from other bispecifics and the need for reimbursement agreements.

Relevance 9/10Novelty 9/10Timing: today

Background

The article reports first‑time disclosure of Phase 3 trial results for epcoritamab plus R‑CHOP in frontline DLBCL.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase 3 EPCORE DLBCL-2 trial results showing a 51% reduction in progression risk.

Expected impact

upward pressure as market prices in the efficacy data

Evidence & confidence

Phase 3 data for a new indication is material and novel, especially for a large pharma.

$GMABBullishHigh confidence
Context

Genmab reported the same Phase 3 EPCORE DLBCL-2 results, highlighting a 51% risk reduction in progression.

Expected impact

upward pressure as investors value the new indication

Evidence & confidence

Genmab co‑developed the drug; trial success directly enhances its pipeline valuation.

Market effects

Sector

Strengthens the oncology/biotech sector outlook, especially for bispecific antibodies.

Regional

Positive for US biotech equities and European partners like Genmab.

Global

Adds confidence to lymphoma treatment pipelines worldwide.

Counterpoint

What could challenge this read

If regulatory hurdles delay approval, the short‑term rally could be limited.

Key entities

  • Company
    AbbVie

    US‑listed biopharma developing epcoritamab.

  • Company
    Genmab

    Partner in epcoritamab development, US‑listed ADR.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 6
$ABBVMed

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

AbbVie (ABBV) shares rose 0.3% to $266.63 on Oct. 6 after a late-stage trial showed its blood-cancer treatment, epcoritamab plus R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone in diffuse large B-cell lymphoma. The trial's hazard ratio was 0.49, with a p-value below 0.0001, and safety was consistent with known profiles.

finance.yahoo.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

theglobeandmail.com2 min
OCT 6
$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min
OCT 6
$ABBVMed

AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.

oncodaily.com2 min